Core Insights - GH Research PLC shares increased by 18.1% to $15.64 in pre-market trading following the announcement of an update on its FDA IND status and Phase 3 program for GH001 in treatment-resistant depression [1] Gainers - MKDWELL Tech Inc surged 61.2% to $0.27 after agreeing to repurchase 34,580,000 ordinary shares at $0.203/share, totaling $7 million [4] - Regencell Bioscience Holdings Ltd gained 52% to $31.21 after a previous decline of 2% [4] - Datavault AI Inc rose 26.7% to $1.28 after a 55% increase on the previous trading day [4] - Sidus Space Inc increased by 21.9% to $5.28 following a 38% rise on Friday [4] - Kazia Therapeutics Ltd rose 21.7% to $6.08 after a 27% decline on Friday [4] - Context Therapeutics Inc gained 18.7% to $1.84 after a 5% increase on Friday [4] - Hyperscale Data Inc rose 18.6% to $0.32 after a 49% jump on Friday [4] - PBF Energy Inc increased by 16.7% to $33.30 after providing updates on Martinez refinery operations and 2026 annual guidance [4] - Bioatla Inc rose 16.1% to $0.62 after a dip of more than 5% on Friday [4] Losers - Salarius Pharmaceuticals Inc fell 21.8% to $0.51 in pre-market trading [4] - Gain Therapeutics Inc decreased by 21.4% to $2.50 [4] - SBC Medical Group Holdings Inc declined 18.9% to $3.51 [4] - Polyrizon Ltd dropped 11.7% to $11.24 after a 50% gain on Friday [4] - ChowChow Cloud International HLDG Ltd dipped 10.3% to $0.71 after a 30% increase on Friday [4] - Lavoro Ltd shares fell 9.1% to $1.00 after a 144% jump on Friday [4] - Vicarious Surgical Inc decreased by 7.9% to $2.32 after a 16% gain on Friday [4] - Theravance Biopharma Inc dipped 6% to $17.07 after a 3% decline on Friday [4] - Comcast Corp tumbled 4.6% to $28.18 [4] - Equinor ASA fell 3.6% to $23.66 after a 4% increase on Friday [4]

Core Viewpoint - The U.S. government is accelerating the development of robotics technology, leading to a significant rise in several robotics stocks, including Nauticus Robotics and iRobot, which both saw increases of over 60% [1][5]. Group 1: Stock Performance - Nauticus Robotics (KITT) rose by 61.92%, reaching a price of $1.1700 [2][4]. - iRobot (IRBT) increased by 61.28%, with a price of $3.145 [2][4]. - Other notable performers include Vicarious Surgical (RBOT) up 15.77%, Lifeward (LFWD) up 13.18%, Serve Robotics (SERV) up 10.87%, and Richtech Robotics (RR) up 10.12% [2][4]. Group 2: Government Initiatives - The U.S. Commerce Secretary has been meeting with various CEOs in the robotics industry, indicating a push for advancements in this sector [5]. - The government is considering an executive order on robotics technology to be announced next year, emphasizing the importance of robotics in bringing critical manufacturing back to the U.S. [3][5]. - A robotics task force is being prepared by the U.S. Department of Transportation, with an announcement expected by the end of the year [3][5]. Group 3: Industry Insights - Robotics is becoming a crucial area of international competition, with rising interest from U.S. lawmakers, including proposals for a national robotics committee [3][5]. - Advances in artificial intelligence are enabling humanoid robots to process large amounts of data and handle increasingly complex tasks, positioning robots as the "physical form" of AI [3][5]. - Industry leaders believe that investing in robotics can lead to greater efficiency for workers and potentially create more job opportunities, as companies that invest in robots are likely to invest in more employees as well [3][5].

Core Viewpoint - The article highlights a significant surge in robot-related stocks, driven by potential government initiatives to advance robotics technology in the U.S. [3][5] Group 1: Stock Performance - Several robotics stocks experienced substantial gains, with Nauticus Robotics and iRobot both rising over 60% [3][4]. - Nauticus Robotics (KITT) increased by 61.92% to $1.1700, while iRobot (IRBT) rose by 61.28% to $3.145 [4]. Group 2: Government Initiatives - The Trump administration is reportedly accelerating the development of robotics technology, with the Commerce Secretary meeting various CEOs in the robotics sector [5]. - There are plans for an executive order on robotics technology to be announced next year, indicating a strong governmental push in this area [5]. - The U.S. Department of Transportation is preparing to establish a robotics working group, potentially announced by the end of the year [5]. Group 3: Industry Implications - The growing interest in robotics is seen as a critical aspect of international competition, although it may conflict with the goal of reviving U.S. manufacturing jobs [5]. - Advances in artificial intelligence are enabling humanoid robots to process data more efficiently and take on complex tasks, positioning robots as the "physical form" of AI [5]. - Industry leaders emphasize the importance of a national robotics strategy to maintain competitiveness in the emerging sector [6].

Company Overview - Glucotrack, Inc. is focused on the design, development, and commercialization of novel technologies for people with diabetes [5] - The company is currently developing a long-term implantable continuous blood glucose monitoring (CBGM) system [5][6] Leadership Addition - Victoria E. Carr-Brendel, PhD, has been elected to Glucotrack's Board of Directors effective May 22, 2025 [1] - Dr. Carr-Brendel brings extensive experience in medical devices and implantable technologies, having held leadership roles at various companies including Vicarious Surgical Inc. and Sonova Group [2][3] Technology Development - Glucotrack's CBGM is designed as a long-term implantable system that provides continuous blood glucose monitoring for up to three years [3][6] - The system measures glucose directly from blood, offering real-time readings without the lag time associated with traditional continuous glucose monitoring systems [3] Strategic Importance - Dr. Carr-Brendel expressed her commitment to contributing to Glucotrack's strategic and clinical milestones, emphasizing the potential of the CBGM to address unmet needs for diabetes management [3]

Financial Data and Key Metrics Changes - Total operating expenses for full year 2024 were $66.6 million, down 17% year-over-year [24] - R&D expenses for the full year 2024 were $40.2 million, down from $47.6 million in 2023 [24] - GAAP net loss for full year was $63.2 million, equating to a net loss of $10.74 per share, compared to a GAAP net loss of $71.1 million or $14.60 per share for the full year 2023 [25] Business Line Data and Key Metrics Changes - General and administrative expenses totaled $21.9 million in the full year 2024, down from $26.9 million in 2023 [24] - Sales and marketing expenses were $4.5 million compared to $6.2 million in the prior year [24] Market Data and Key Metrics Changes - The company has expanded its partnerships with leading U.S. hospital systems, including LSU Health New Orleans, Temple Health, and University of Illinois Health [13][15] - The company is preparing for its first clinical use of the Version 1.0% system, which is expected to treat patients later in the year [21] Company Strategy and Development Direction - The company aims to transition into a clinical stage company in 2025, with a focus on robotic surgery innovations [8] - The Version 1.0% system is designed to deliver differentiated value to patients, surgeons, and hospitals, with a focus on minimally invasive outcomes [10][12] - The company is building a robust supply chain and manufacturing foundation to support its clinical trials and future growth [18][19] Management's Comments on Operating Environment and Future Outlook - Management expressed excitement about the successful completion of the Version 1.0% system integration and the potential impact on surgical procedures [9][28] - The company anticipates treating its first clinical patients by year-end 2025, with a de novo submission expected to be late in 2026 [21][26] Other Important Information - The company has faced some procurement challenges with key suppliers, but has managed to mitigate the impact on its timelines [20][36] - A new CFO, Sarah Romano, will join the company on April 1, bringing extensive financial leadership experience [22][23] Q&A Session Summary Question: Can you provide details on the supplier dynamic and its impact on clinical trial manufacturing? - Management acknowledged material procurement challenges with key suppliers that led to delays in component deliverables, but noted that they have resumed production [35][37] Question: When do you anticipate the clinical trial beginning? - Management indicated that the first patients will be treated later in the year, with plans to kick off pivotal trials shortly after [41][42] Question: Can you provide timing around the dossier submission? - The dossier submission is expected around the middle of the year, with the first patient timing dependent on approval [51] Question: What were the results of the cadaver lab tests? - The cadaver labs successfully performed ventral hernia repairs, and management expressed confidence in the system's performance [61] Question: Any updates on clinical trial design and patient expectations? - Management confirmed that trial design will be finalized after the first patients, allowing for flexibility in protocol adjustments [64]